| 1 |
Silva SB, Wanderley CWS, Colli LM. Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy. Front Immunol 2022;13:826577. [PMID: 35211121 DOI: 10.3389/fimmu.2022.826577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Di Nardo P, Garattini SK, Torrisi E, Fanotto V, Miolo G, Buonadonna A, Puglisi F. Systemic Treatments for Advanced Small Bowel Adenocarcinoma: A Systematic Review. Cancers (Basel) 2022;14:1502. [PMID: 35326652 DOI: 10.3390/cancers14061502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Koulouris A, Tsagkaris C, Nikolaou M. Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years. Toxins (Basel) 2021;13:149. [PMID: 33672017 DOI: 10.3390/toxins13020149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 4 |
Sacdalan DB, Mendoza MJ, Vergara JP, Catedral LI, Ting FI, Leones LM, Berba CM, Sacdalan DL. Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma. Med Oncol 2020;37:106. [PMID: 33135102 DOI: 10.1007/s12032-020-01432-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 5 |
Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol 2020;72:353-63. [PMID: 31954497 DOI: 10.1016/j.jhep.2019.10.009] [Cited by in Crossref: 144] [Cited by in F6Publishing: 145] [Article Influence: 48.0] [Reference Citation Analysis]
|
| 6 |
Jun SY, Park ES, Lee JJ, Chang HK, Jung ES, Oh YH, Hong SM. Prognostic Significance of Stromal and Intraepithelial Tumor-Infiltrating Lymphocytes in Small Intestinal Adenocarcinoma. Am J Clin Pathol 2020;153:105-18. [PMID: 31576398 DOI: 10.1093/ajcp/aqz136] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 7 |
Huber M, Huber B. Innovation in Oncology Drug Development. J Oncol 2019;2019:9683016. [PMID: 31911803 DOI: 10.1155/2019/9683016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 8 |
Goto T, Hirotsu Y, Amemiya K, Mochizuki H, Omata M. Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach. Cancers (Basel) 2018;10:E212. [PMID: 29932159 DOI: 10.3390/cancers10070212] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 9 |
Chang L, Chang M, Chang HM, Chang F. Expending Role of Microsatellite Instability in Diagnosis and Treatment of Colorectal Cancers. J Gastrointest Cancer 2017;48:305-13. [PMID: 28699072 DOI: 10.1007/s12029-017-9991-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Nakagomi T, Goto T, Hirotsu Y, Shikata D, Yokoyama Y, Higuchi R, Amemiya K, Okimoto K, Oyama T, Mochizuki H, Omata M. New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. Oncotarget. 2018;9:10635-10649. [PMID: 29535832 DOI: 10.18632/oncotarget.24365] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 11 |
Yuza K, Nagahashi M, Watanabe S, Takabe K, Wakai T. Hypermutation and microsatellite instability in gastrointestinal cancers. Oncotarget 2017;8:112103-15. [PMID: 29340115 DOI: 10.18632/oncotarget.22783] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 12 |
Jun SY, Lee EJ, Kim MJ, Chun SM, Bae YK, Hong SU, Choi J, Kim JM, Jang KT, Kim JY, Kim GI, Jung SJ, Yoon G, Hong SM. Lynch syndrome-related small intestinal adenocarcinomas. Oncotarget 2017;8:21483-500. [PMID: 28206961 DOI: 10.18632/oncotarget.15277] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 13 |
Lee V, Murphy A, Le DT, Diaz LA Jr. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. Oncologist 2016;21:1200-11. [PMID: 27412392 DOI: 10.1634/theoncologist.2016-0046] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 14 |
Lee V, Murphy A, Le DT, Diaz LA Jr. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. Oncologist. 2016;21:1200-1211. [PMID: 27412392 DOI: 10.1634/theoncologist.2016-0046] [Cited by in Crossref: 149] [Cited by in F6Publishing: 167] [Article Influence: 21.3] [Reference Citation Analysis]
|
| 15 |
Underhill ML, Germansky KA, Yurgelun MB. Advances in Hereditary Colorectal and Pancreatic Cancers. Clin Ther 2016;38:1600-21. [PMID: 27045993 DOI: 10.1016/j.clinthera.2016.03.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 16 |
Warth A, Körner S, Penzel R, Muley T, Dienemann H, Schirmacher P, von Knebel-Doeberitz M, Weichert W, Kloor M. Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases. Virchows Arch 2016;468:313-9. [PMID: 26637197 DOI: 10.1007/s00428-015-1892-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 17 |
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015;372:2509-20. [PMID: 26028255 DOI: 10.1056/NEJMoa1500596] [Cited by in Crossref: 6057] [Cited by in F6Publishing: 6105] [Article Influence: 757.1] [Reference Citation Analysis]
|
| 18 |
Wang J, Reiss KA, Khatri R, Jaffee E, Laheru D. Immune Therapy in GI Malignancies: A Review. J Clin Oncol. 2015;33:1745-1753. [PMID: 25918295 DOI: 10.1200/jco.2015.60.7879] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 19 |
Thompson BA, Spurdle AB. Microsatellite instability use in mismatch repair gene sequence variant classification. Genes (Basel) 2015;6:150-62. [PMID: 25831438 DOI: 10.3390/genes6020150] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 20 |
Prasad MA, Jung B. Microsatellite Instability and Intestinal Tumorigenesis. Intestinal Tumorigenesis 2015. [DOI: 10.1007/978-3-319-19986-3_2] [Reference Citation Analysis]
|
| 21 |
Cohen SA, Leininger A. The genetic basis of Lynch syndrome and its implications for clinical practice and risk management. Appl Clin Genet. 2014;7:147-158. [PMID: 25161364 DOI: 10.2147/tacg.s51483] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
|
